Covid-19 Self Test Kit We are the authorized first vendor of ADTech! KFDA CE approved, FDA Pending Price : Negotiable Pre-Clinical Test Report Accuracy - In total samples 93.3% (14/15) - In positive samples 91.7% (11/12) 1. Pre-Clinical Test summary 1) Pre-clinical test is fulfilled by Domestic large clinical laboratory with ADTech COVID-19 IgM/IgG RAPID KIT 2) Tests are made by total 15 samples with 12 positive and 3 negative samples 3) Clinical Laboratory tested the sample with Immunofluorescence Analysis 2. Pre-clinical test result 1) Samples were tested by ADTech COVID-19 IgM/IgG RAPID KIT 2) Test result by ADTechs RAPID KIT - 4 negatives and 11 positives results in 15 samples 3) Comparison between Immunofluorescence analysis and ADTechs RAPID KIT - 14 test results are same(including negative and positive results) - 1 samples test result are different(Positive Negative by ADTech
What is Home-Check Menopause test? This is a home-use test kit to measure Follicle Stimulating Hormone (FSH) in your urine. This may help indicate if you are in menopause or perimenopause. Why should you do this Home-Check Menopause test? You should use this test if you want to know if your symptoms, such as irregular periods, hot flushes, vaginal dryness, or sleep problems are due to high levels of FSH which may be part of menopause. While many women may have little or no trouble when going through the stages of menopause, others may have moderate to severe discomfort and may want treatment to alleviate their symptoms. This test may help you be better informed about your current condition when you see your doctor. Key Features * Over 99% accurate* * Fast results – within minutes * Convenient * AUST L 174939 - approved by the TGA, European authorities and Indian FDA * Detects FSH levels higher than 25mlU/ml. Pack Contains: 1 In-stream Home-Check Menopause Menopause Test 1 Instruction Leaflet. Precautions: For external use only Always read the label Use only as directed. *In laboratory and consumer clinical studies.
Angiten-COVID-19 Virus Test Kit (Colloidal Gold) Quantity of box: 25 persons/box Brand: Easysweet NMPA (National Medical Products Administration): Approved CE: with CE mark BfArM: listed Test Method: Antigen Test Result Time: 10-15 mins Sample Type: Nasal Swab Sensitivity: 96.70% Specificity: 100% Accuracy: 98.94% Shelf Life: 24 months Storage Temperature: 2-30 Degree Celsius Country of Origin: Made in China Additional Information: Production Capacity: 1 million Delivery Time: 10-15 days Packaging Details: 25 tests in a pack, 40packs/ carton Angiten-COVID-19 Virus Test Kit is an in vitro diagnostic rapid test for the qualitative detection of SARS-CoV-2 antigen (Ag) in human nasopharyngeal swab specimens from individuals who meet COVID-19clinical and / or epidemiological criteria. It can be used by professional only. Price and Minumum Quantity Price FOB in USD: NegotiableMinimum Order Qty: 10000 Production Capacity: 1000000Packaging: 25 Persons/box Sample: Available. Sample Cost Born By Buyer Product Model And Origin Brand: Easysweet HS Code: 3822009020 Standards: Ce Competitive Advantages Best price with shortest delivery time Best price with shortest delivery time Best price with shortest delivery time Best price with shortest delivery time Other Details Angiten-covid-19 virus test kit (colloidal gold) Angiten-covid-19 virus test kit (colloidal gold) Angiten-covid-19 virus test kit (colloidal gold) Angiten-covid-19 virus test kit (colloidal gold)
Access Bio Care Start Covid-19 Rapid Antigen Test Kit Product Details: Number of Reactions(Preps) per Kit : 1 Brand : Access Bio Test Method : Antigen Test Result Time (Rapid Kits) : 10 min Sample Type ; Nasal Swab Packaging Size : 20 Test Kits/Box Packaging Type : Box The CareStart COVID-19 Antigen test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within first five days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between